Who Exports Imatinib from India — 224 Suppliers Behind a $29.3M Market
India's imatinib export market is supplied by 224 active exporters who collectively shipped $29.3M across 1,726 shipments. CIPLA LIMITED leads with a 36.4% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 81.2% of total export value, reflecting a concentrated market structure.
Top Imatinib Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading imatinib exporter from India, holding a 36.4% share of the $29.3M market across 1,726 shipments from 224 exporters. The top 5 suppliers — CIPLA LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, JODAS EXPOIM PRIVATE LIMITED, NATCO PHARMA LIMITED — collectively control 81.2% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (36.4%), EUGIA PHARMA SPECIALITIES LIMITED (21.1%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (9.9%), JODAS EXPOIM PRIVATE LIMITED (9.4%), NATCO PHARMA LIMITED (4.5%).
Top Imatinib Exporters from India
Ranked by export value · 224 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED IMATINIB ORION 100MG CAPSULES PACK SIZE 12 X 10SIMATIB ALPHA 100 CAPSULESIMAVEC 400MG CAPSULLES [3825X3X10'S]NOS | $10.6M | 8 | 36.4% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED IMATINIB MESYLATE TABLETS 400 MG IMATINIMATINIB MESYLATE TABLETS 400 MGIMATINIB MESYLATE TABLETS 400 MG - US | $6.2M | 2 | 21.1% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED IMATINIB ORION 100MG CAPSULES PACK SIZE 12 X 10SIMATINIB MESYLATE TABLETS 400MG (IMATINIIMATINIB GH 400 MG CAPSULES | $2.9M | 7 | 9.9% |
| 4 | JODAS EXPOIM PRIVATE LIMITED IMATINIB TABLETS 400MGIMATINIB TABLETS 100MG | $2.7M | 3 | 9.4% |
| 5 | NATCO PHARMA LIMITED | $1.3M | 9 | 4.5% |
| 6 | INTAS PHARMACEUTICALS LIMITED IMATINIB 400MG 3X10T ALU ACCORD-PP-ESIMATINIB 400MG 3X10T ALU (ACCORD-PP-ESIMATINIB AMAROX 400MG | $857.6K | 6 | 2.9% |
| 7 | ACCURE LABS PRIVATE LIMITED IMATINIB COOPER 100 MG CAPSULES ( IMATINIMATINIB COOPER 100 MG CAPSULES 100MG) [1133X10X10'S]IMATINIB COOPER 100 MG CAPSULES IMATIN | $629.7K | 2 | 2.2% |
| 8 | HETERO LABS LIMITED IMATINIB AMAROX 400MGIMATINIB400MG 3X10T ALU ACCORD-PP-DEIMATINIB 400MG | $291.4K | 2 | 1.0% |
| 9 | INTAS PHARMACEUTICALS LTD IMATINIB 400MG 3X10T ALU ACCORD-PP-ESIMATINIB 400MG 3X10T ALU (ACCORD-PP-ESIMATINIB AMAROX 400MG | $284.7K | 5 | 1.0% |
| 10 | DR REDDYS LABORATORIES LIMITED IMATINIB MESYLATE TABLETS 400MG (IMATINIIMATINIB GH 400 MG CAPSULESIMATINIB MESYLATE TABLETS 100MG (IMATINI | $263.8K | 3 | 0.9% |
| 11 | VHB MEDISCIENCES LTD | $250.6K | 1 | 0.9% |
| 12 | MSN LABORATORIES PRIVATE LIMITED | $219.5K | 3 | 0.7% |
| 13 | VEXXA LIFESCIENCES PVT. LTD. IMALEK TAB 100MG TABLETS (IMATINIB MESYLIMALEK 100MG TABLETS [17740 PACK X1X10]IMALEK TAB 100MG IMATINIB MESYLATE TABL | $204.3K | 2 | 0.7% |
| 14 | SUN PHARMACEUTICAL INDUSTRIES LTD IMATINIB ORION 100MG CAPSULES PACK SIZE 12 X 10SIMATINIB MESYLATE TABLETS 400MG (IMATINIIMATINIB GH 400 MG CAPSULES | $170.3K | 1 | 0.6% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Imatinib exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla has received FDA approvals for various drugs and holds WHO-GMP and EU GMP |
| EUGIA PHARMA SPECIALITIES LIMITED | Approved | Yes | Yes | Multiple | Eugia Pharma has FDA approvals for several drugs and maintains WHO-GMP and EU GM |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | Multiple | Sun Pharma holds FDA approvals for various drugs and possesses WHO-GMP and EU GM |
| NATCO PHARMA LIMITED | Approved | Yes | Yes | Multiple | Natco Pharma has received FDA approvals and holds WHO-GMP and EU GMP certificati |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Intas Pharmaceuticals holds FDA approvals and maintains WHO-GMP and EU GMP certi |
| HETERO LABS LIMITED | Approved | Yes | Yes | Multiple | Hetero Labs has FDA approvals and holds WHO-GMP and EU GMP certifications. |
| DR REDDYS LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | Dr. Reddy's Laboratories holds FDA approvals and maintains WHO-GMP and EU GMP ce |
| MSN LABORATORIES PRIVATE LIMITED | Approved | Yes | Yes | Multiple | MSN Laboratories has FDA approvals and holds WHO-GMP and EU GMP certifications. |
| SUN PHARMACEUTICAL INDUSTRIES LTD | Approved | Yes | Yes | Multiple | Sun Pharmaceutical Industries Ltd holds FDA approvals and maintains WHO-GMP and |
TransData Nexus reviewed the regulatory standing of 9 leading Imatinib exporters from India. 9 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Imatinib sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma City of India," is a central hub for pharmaceutical research, manufacturing, and exports. The city contributes nearly 40% of the country's bulk drug production and hosts over 2,000 pharmaceutical companies. Notable firms such as Dr. Reddy's Laboratories, Natco Pharma, and Aurobindo Pharma are headquartered here, significantly influencing the production and export of Imatinib. The presence of Genome Valley, a premier biotech cluster with world-class infrastructure, further bolsters Hyderabad's position as a leader in pharmaceutical innovation and manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its robust pharmaceutical industry, accounting for 33% of India's drug manufacturing and 28% of drug exports. This region is home to major companies like Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Ltd., and Zydus Cadila Healthcare Ltd., which are instrumental in the formulation and export of medications, including Imatinib. The state's commitment to pharmaceutical excellence is evident in its 130 USFDA-certified drug manufacturing facilities, underscoring its pivotal role in the global pharmaceutical supply chain.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being the financial capital, provides essential infrastructure and connectivity for pharmaceutical exports. The region hosts several pharmaceutical giants, including Cipla Limited, which is a leading exporter of Imatinib. The strategic location and well-established logistics network make this cluster vital for the distribution of pharmaceuticals to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives and supportive government policies. This zone attracts numerous pharmaceutical companies seeking cost-effective production solutions. While not directly linked to the top exporters of Imatinib, the region's contribution to the overall pharmaceutical manufacturing capacity enhances India's ability to meet global demand for various medications.
5Sourcing Recommendations
- Engage with Leading Manufacturers: Establish partnerships with top Imatinib exporters such as Cipla Limited, EUGIA Pharma Specialities Limited, and Sun Pharmaceutical Industries Limited to ensure a reliable supply chain.
- Leverage Cluster Specializations: Utilize the bulk drug production capabilities of Hyderabad and the formulation expertise of the Ahmedabad-Vadodara corridor to optimize sourcing strategies.
- Optimize Export Logistics: Capitalize on the export infrastructure of the Mumbai-Thane-Raigad region to facilitate efficient international distribution of Imatinib.
- Monitor Regulatory Compliance: Ensure all sourcing activities adhere to the guidelines set forth by regulatory bodies such as the Central Drugs Standard Control Organisation (CDSCO) and the Directorate General of Foreign Trade (DGFT) to maintain compliance and product quality.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Imatinib exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. - IMPACT: This acquisition is expected to enhance Sun Pharma's product portfolio and manufacturing capabilities, potentially increasing its Imatinib export capacity.
Impact: This acquisition is expected to enhance Sun Pharma's product portfolio and manufacturing capabilities, potentially increasing its Imatinib export capacity.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma announced the acquisition of Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million. - IMPACT: This acquisition may bolster Sun Pharma's oncology pipeline, potentially affecting its Imatinib production and export strategies.
Impact: This acquisition may bolster Sun Pharma's oncology pipeline, potentially affecting its Imatinib production and export strategies.
Cipla Limited — Cipla acquires Ivia Beaute's personal care brands
Cipla acquired the distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore, expanding its consumer wellness portfolio. - IMPACT: While this acquisition focuses on consumer wellness, it may indirectly influence Cipla's resource allocation and strategic focus, potentially impacting Imatinib exports.
Impact: While this acquisition focuses on consumer wellness, it may indirectly influence Cipla's resource allocation and strategic focus, potentially impacting Imatinib exports.
Common Questions — Imatinib Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which imatinib supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 103 recorded shipments worth $10.6M. EUGIA PHARMA SPECIALITIES LIMITED (82 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (72 shipments) are also established high-volume exporters.
Q How many imatinib manufacturers are there in India?
India has 224 active imatinib exporters with a combined export market of $29.3M across 1,726 shipments to 119 countries. The top 5 suppliers hold 81.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for imatinib from India?
Average FOB unit price: $16.53 per unit, ranging from $0.01 to $1869.22. Average shipment value: $17.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 224 verified Indian exporters of Imatinib ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,726 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 119 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,726 Verified Shipments
224 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists